Great volume (90m). Positive financials for 2Q should be out in the next weeks. Interim safety analysis due 2H 2017. Looks good, longs. Buy and hold.
Steve Clark--- "The specialty pharmaceutical and medical device company will release Phase 2 clinical data for a combination of Melphalan and its Hepatic Delivery System before the end of the month. The treatment is being developed as a novel treatment for cancer of the liver and bile duct. Delcath Systems, Inc. (NASDAQ:DCTH) is also testing Melphalan Hydrochloride in a phase 3 clinical trial in patients with Ocular Melanoma. Developments in the oncology space should have a significant impact on the stock once the short sale circuit breaker is withdrawn."
Wait for the huge volume that will take this even higher after 8 am....go DCTH👍👍
When I sell, it goes up, and when I buy, it goes down. I'll just give you guys a heads up on what I'm about to do....
there product is SUCCESSFUL in Europe. big pharma buyout coming
I like the summary that insider trading has posted on the 26th... In other words, the company now asking shareholders to take a position based on the science as opposed to the potential for mismanagement and dilution. While it’s far from a sure thing, it’s a $26 million company with two very late stage assets in development in large, unmet healthcare indications. Take this valuation into consideration against the backdrop of some of its peers, and it looks plenty cheap at current prices.
not to sound greedy, but if it could hit $16.00-$20.00 today I wouldn't complain. haha
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer - Full Text View - ClinicalTrials.gov No Wonder the volume is so high lately , Something Positive will get it to around a dollar fast!
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer - Full Text View - ClinicalTrials.gov